Skip to main content
. 2022 Mar 28;43(10):2609–2623. doi: 10.1038/s41401-022-00898-3

Fig. 7. Knockdown of Klotho significantly aggravated renal fibrosis in UUO mice (n = 6–8).

Fig. 7

a, b Kidney expression of Klotho from mice injected with AAV9 carrying shRNA against Klotho or control vector as assayed by Western blotting (three samples in each group). c Renal expression of Klotho mRNA in different groups as assessed by real-time PCR. d Representative photomicrographs of the H&E staining and Masson’s trichrome staining from the left kidneys of negative control and Klotho shRNA mice (H&E and Masson’s staining; scale bar, 100 μm). e, f Biochemical parameters, including blood urea nitrogen (BUN) and serum creatinine (Scr), of each mouse. g Kidney expression of fibronectin, collagen III and α-SMA from sham, UUO and Klotho shRNA-treated UUO mice as assayed by Western blotting (three samples in each group). h–j Quantification analysis of (g). k Representative photomicrographs of the H&E staining and Masson’s trichrome staining of the left kidneys from Sham, UUO and Klotho shRNA-treated UUO mice (H&E and Masson’s staining; scale bar, 100 μm). l, m Quantification analysis of (k). n, o Biochemical parameters, including blood urea nitrogen (BUN) and serum creatinine (Scr), of each mouse. p–y Kidney expression levels of Smad2, Smad3, phospho-Smad2, phospho-Smad3, active β-catenin, β-catenin, DVL2 and DVL3 from sham, UUO and Klotho shRNA-treated UUO mice were assayed by Western blotting (three samples in each group). Results are means ± SD of at least three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 (compared with the sham group); #P < 0.05; ##P < 0.01; ###P < 0.001 (compared with the UUO group).